Myomo Raises $6M in Direct Stock Offering

January 22, 2024: Myomo, Inc. (NYSE: MYO), a pioneering developer of wearable medical robots for individuals with neurological disorders and upper-limb paralysis, has secured a strategic $6 million capital injection through a registered direct offering of its common stock. This financial maneuver provides a vital boost to the company’s growth trajectory, enabling it to scale up operations and capitalize on a burgeoning market opportunity.

The offering, which closed on or about January 19, 2024, attracted participation from new and existing institutional investors and certain company insiders. The proceeds and Myomo’s existing cash reserves are expected to fuel the company’s ambitious expansion plans.

By leveraging these additional resources, Myomo intends to:

• Expand its clinical and reimbursement capabilities: This will involve hiring additional personnel to support increased patient enrollment in clinical trials and streamline the insurance reimbursement process for the company’s flagship MyoPro product.
• Ramp up manufacturing capacity: To meet anticipated demand for the MyoPro, Myomo will invest in its manufacturing infrastructure, ensuring efficient production and timely delivery to patients.
• Strengthen its sales and marketing efforts: Focused outreach to healthcare professionals and patients will raise awareness of MyoPro’s transformative potential, solidifying its position in the growing market for neurorehabilitation technologies.

The capital infusion arrives at a crucial juncture for Myomo. The recent establishment of Medicare coverage for MyoPro and the proposed pricing guidelines have opened up a vast new market segment for the company. By effectively scaling its operations, Myomo can capitalize on this favorable regulatory landscape and establish itself as a key player in rehabilitation.

Beyond internal expansion, the additional capital could pave the way for strategic partnerships or acquisitions. This would allow Myomo to broaden its product portfolio or strengthen its existing technology with complementary offerings, propelling its overall growth strategy.

While Myomo’s future remains intertwined with factors like market adoption, reimbursement processes, and potential regulatory headwinds, the successful completion of the direct stock offering underscores the company’s solid financial footing and promising market prospects. By strategically deploying these newly secured funds, Myomo is poised to further its mission of providing life-changing mobility solutions to individuals with upper-limb limitations.